Brain cell transplantation research has shown that structural and functional repair of the adult brain is possible. We are testing the functional hypothesis that embryonic striatal neurons can replace neurons lost in adult primate striatum and improve signs of Huntinton's disease (HD). The lack of an optimal human donor cell source in a clinical scenario has led us to utilize zenogeneic (here transgenic pig) embryonic donor cells. Our preliminary in vivo data show that successful xenografts survival in the primate brain requires immunosuppression by cyclosporine, azathiopirne, methylprednisolone and complement inhibition (CD59 transgenic donor tissue and monoclonal antibodies against complement C5). To test the functional hypothesis, we proposed the following experiments: We will transplant CD59 complement aggregation inhibitor expressing transgenic porcine fetal striatal (E35 LGE) cells to the caudate-putamen of non-human primate (Macaca mulatta) with neuronal loss similar to that seen in HD. To determine how functional recovery depends on survival and growth of porcine striatal transplants, we will collect physiological in vivo data by PET/MRI/MRS and behavioral data by examining motor and cognitive function. The physiological analysis of LBE graft function by in vivo imaging and behavioral assays is followed by detailed morphological studies. Combine, these studies will provide essential data on the relationship between structural and functional integration of embryonic neuronal xenografts in a HD primate model. These experiments will improve our knowledge of basal ganglia function and plasticity, as well as determine parameters for optimal cell transplantation in patients with neurological disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS030064-08
Application #
6393490
Study Section
Special Emphasis Panel (ZRG1-BDCN-2 (01))
Program Officer
Oliver, Eugene J
Project Start
1992-01-01
Project End
2003-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
8
Fiscal Year
2001
Total Cost
$355,500
Indirect Cost
Name
Mc Lean Hospital (Belmont, MA)
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02478
Seo, Hyemyung; Kim, Woori; Isacson, Ole (2008) Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum Mol Genet 17:3144-53
Seo, Hyemyung; Sonntag, Kai-Christian; Isacson, Ole (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 56:319-28
Isacson, Ole; Bjorklund, Lars M; Schumacher, James M (2003) Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol 53 Suppl 3:S135-46; discussion S146-8
Cicchetti, F; Fodor, W; Deacon, T W et al. (2003) Immune parameters relevant to neural xenograft survival in the primate brain. Xenotransplantation 10:41-9
Bjorklund, Lars M; Isacson, Ole (2002) Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res 138:411-20
Cicchetti, F; Costantini, L; Belizaire, R et al. (2002) Combined inhibition of apoptosis and complement improves neural graft survival of embryonic rat and porcine mesencephalon in the rat brain. Exp Neurol 177:376-84
Haque, N S; Isacson, O (2000) Neurotrophic factors NGF and FGF-2 alter levels of huntingtin (IT15) in striatal neuronal cell cultures. Cell Transplant 9:623-7
Freeman, T B; Cicchetti, F; Hauser, R A et al. (2000) Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc Natl Acad Sci U S A 97:13877-82
Isacson, O; Deacon, T (1997) Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurosci 20:477-82
Haque, N S; Borghesani, P; Isacson, O (1997) Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder. Mol Med Today 3:175-83

Showing the most recent 10 out of 43 publications